Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs. 2909.00, up by 5.10 points or 0.18% from its previous closing of Rs. 2903.90 on the BSE.

The scrip opened at Rs. 2887.60 and has touched a high and low of Rs. 2926.20 and Rs. 2887.60 respectively. So far 3633 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 2965.20 on 02-May-2019 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2965.20 and Rs. 2887.60 respectively. The current market cap of the company is Rs. 48365.88 crore.

The promoters holding in the company stood at 26.77%, while Institutions and Non-Institutions held 45.46% and 13.66% respectively.

Dr. Reddy's Laboratories has launched Testosterone Gel 1.62%, a therapeutic equivalent generic version of AndroGel (testosterone gel) 1.62%, approved by the US Food and Drug Administration (USFDA).

The AndroGel (testosterone gel) brand and generic had US sales of approximately $815.6 million MAT for the most recent twelve months ending in February 2019 according to IQVIA Health.

Dr. Raddy's Testosterone Gel 1.62% (20.25 mg/1.25 g pump actuation) is available in a net quantity of 88 g pump which dispenses 20.25 mg of testosterone per actuation. Each metered-dose pump is capable of dispensing 60 metered pump actuations.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.